icatibant acetate, 30mg, solution for injection in pre-filled syringe (Firazyr®
SMC No 1332/18 Shire Human Genetic Therapies
There were no declarations of interest recorded in relation to this product/comparator drugs.
The NDC Co-Vice Chair provided an overview of the assessment, and draft advice. Detailed
discussion followed and, after a vote of the members, it was decided that icatibant acetate
(Firazyr®), should be accepted for use within NHS Scotland.
Indication under review: symptomatic treatment of acute attacks of hereditary angioedema
(HAE) in adolescents and children aged 2 years and older, with C1-esterase-inhibitor
SMC has previously accepted icatibant acetate for use in adults.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that
improves the cost-effectiveness of icatibant. This SMC advice is contingent upon the
continuing availability of the Patient Access Scheme in NHS Scotland.
The SMC advice will be issued to the NHS Boards and ADTCs on Friday, 6 April 2018.
lijkt mij dan zeer sterk als ze Rocu niet goedkeuren...